A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
- DOI
- 10.1002/ijc.30049
- Published
- 2016 Jul 1
- Container
- International journal of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/ijc.30049,
title = {A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.},
author = {Eng C and Bessudo A and Hart LL and Severtsev A and Gladkov O and Müller L and Kopp MV and Vladimirov V and Langdon R and Kotiv B and Barni S and Hsu C and Bolotin E and von Roemeling R and Schwartz B and Bendell JC},
year = {2016},
journal = {International journal of cancer},
doi = {10.1002/ijc.30049},
url = {https://doi.org/10.1002/ijc.30049}
}RIS
TY - JOUR TI - A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. AU - Eng C AU - Bessudo A AU - Hart LL AU - Severtsev A AU - Gladkov O AU - Müller L AU - Kopp MV AU - Vladimirov V AU - Langdon R AU - Kotiv B AU - Barni S AU - Hsu C AU - Bolotin E AU - von Roemeling R AU - Schwartz B AU - Bendell JC PY - 2016 JO - International journal of cancer DO - 10.1002/ijc.30049 UR - https://doi.org/10.1002/ijc.30049 ER -
APA
C, E., A, B., LL, H., A, S., O, G., L, M., MV, K., V, V., R, L., B, K., S, B., C, H., E, B., R, V. R., B, S., & JC, B. (2016). A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.. International journal of cancer. https://doi.org/10.1002/ijc.30049
Source records
- pubmed · retrieved 2026-09-27T00:30:26.832Z